The University of California, Davis announced Tuesday its plans for a partnership with a federally approved pharmaceutical company “to analyze the chemical and biological profiles of cannabis for the benefit of law enforcement, health care providers and scientific professionals.”
Researchers at the school will collaborate with Biopharmaceutical Research Company, which is registered with the Drug Enforcement Agency, in analyzing “legally acquired cannabis materials” to develop a better understanding of tetrahydrocannabinol or THC, cannabidiol or CBD, and other cannabinoids. The partnership is said to be the first of its kind.
In its announcement Tuesday, the school said that researchers at UC Davis and BRC “will evaluate existing chemistry methods to analyze cannabis and identify the most precise, accurate and reproducible methods for standardization, using diverse Cannabis sativa.” The announcement noted that there “will be no cannabis on the UC Davis campus or any UC Davis-owned or leased property as part of this research.”
The research findings will ultimately be provided to the government and health care providers to enhance regulatory policies and develop a better understanding of medical cannabis treatments.
The partnership is just one of many recent endeavors aimed at closing the gap in cannabis research, which is beginning to